Non-coding landscapes of colorectal cancer

World Journal of Gastroenterology

Volumn 21, Issue 41, 2015, Pages 11709-11739

  Ragusa, Marco ^a   Barbagallo, Cristina ^a   Statello, Luisa ^a   Condorelli, Angelo Giuseppe ^a   Battaglia, Rosalia ^a   Tamburello, Lucia ^a   Barbagallo, Davide ^a   Di Pietro, Cinzia ^a   Purrello, Michele ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Circular RNAs; Colorectal cancer; Diagnosis; Long noncoding RNAs; MicroRNA; Prognosis; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CIRCULAR RNA; LONG UNTRANSLATED RNA; MICRORNA; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; RNA; TUMOR MARKER;

ARTICLE; BODY FLUID; CANCER DIAGNOSIS; CANCER PROGNOSIS; CELL LEVEL; CLINICAL FEATURE; COLORECTAL CANCER; GENETIC ASSOCIATION; HUMAN; MOLECULAR PATHOLOGY; MOLECULAR SIZE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOLOGY; PROTEIN FUNCTION; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; ANIMAL; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC PREDISPOSITION; GENETICS; HUMAN GENOME; MOLECULAR DIAGNOSIS; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

ANIMALS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; RNA, NEOPLASM; RNA, UNTRANSLATED;

EID: 84947226480     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i41.11709     Document Type: Article

References (357)

1. Jacob F, Monod J. Genetic r egulatory mechanisms in the synthesis of proteins. J Mol Biol 1961; 3: 318-356 [PMID: 13718526]
2. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931-945 [PMID: 15496913]
3. Ezkurdia I, Juan D, Rodriguez JM, Frankish A, Diekhans M, Harrow J, Vazquez J, Valencia A, Tress ML. Multiple evidence strands suggest that there may be as few as 19,000 human proteincoding genes. Hum Mol Genet 2014; 23: 5866-5878 [PMID: 24939910 DOI: 10.1093/hmg/ddu309]
4. Szymanski M, Barciszewski J. RNA regulation in mammals. Ann N Y Acad Sci 2006; 1067: 461-468 [PMID: 16804027]
5. Prasanth KV, Spector DL. Eukaryotic regulatory RNAs: an answer to the ' genome complexity' conundrum. Genes Dev 2007; 21: 11-42 [PMID: 17210785]
6. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767 [PMID: 2188735]
7. Gatenby RA, Vincent TL. An evolutionary model of carcinogenesis. Cancer Res 2003; 63: 6212-6220 [PMID: 14559806]
8. Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000; 190: 412-416 [PMID: 10699988]
9. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landsca pes of human breast and colorectal cancers. Science 2007; 318: 1108-1113 [PMID: 17932254]
10. Zhou D, Yang L, Zheng L, Ge W, Li D, Zhang Y, Hu X, Gao Z, Xu J, Huang Y, H u H, Zhang H, Zhang H, Liu M, Yang H, Zheng L, Zheng S. Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. PLoS One 2013; 8: e53310 [PMID: 23301059 DOI: 10.1371/journal.pone.0053310]
11. Hangauer MJ, Vaughn IW, McManus MT. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet 2013; 9: e1003569 [PMID: 23818866 DOI: 10.1371/journal.pgen.1003569]
12. Jacquier A. The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs. Nat Rev Genet 2009; 10: 833-844 [PMID: 19920851 DOI: 10.1038/nrg2683]
13. Amaral PP, Dinger ME, Mercer TR, Mattick JS. The eukaryotic genome as an RNA machine. Science 2008; 319: 1787-1789 [PMID: 18369136 DOI: 10.1126/science.1155472]
14. Yazgan O, Krebs JE. Noncoding but nonexpendable: transcriptional regulation by large noncoding RNA in eukaryotes. Biochem Cell Biol 2007; 85: 484-496 [PMID: 17713583]
15. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol 2010; 220: 126-139 [PMID: 19882673 DOI: 10.1002/path.2638]
16. Liu Y, Ferguson JF, Xue C, Ballantyne RL, Silverman IM, Gosai SJ, Serfecz J, Morley MP, Gregory BD, Li M, Reilly MP. Tissuespecific RNA-Seq in human evoked inflammation identifies blood and adipose LincRNA signatures of cardiometabolic diseases. Arterioscler Thromb Vasc Biol 2014; 34: 902-912 [PMID: 24504737 DOI: 10.1161/ATVBAHA.113.303123]
17. Wu P, Zuo X, Deng H, Liu X, Liu L, Ji A. Roles of long noncoding RNAs in brain developme nt, functional diversification and neurodegenerative diseases. Brain Res Bull 2013; 97: 69-80 [PMID: 23756188 DOI: 10.1016/j.brainresbull.2013.06.001]
18. Malek E, Jagannathan S, Driscoll J J. Correlation of long noncoding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget 2014; 5: 8027-8038 [PMID: 25275300]
19. Raza U, Zhang JD, Sahin O. MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med (Berl) 2014; 92: 321-336 [PMID: 24509937 DOI: 10.1007/s00109-014-1129-2]
20. Crea F, Clermont PL, Parolia A, Wang Y, Helgason CD. The noncoding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev 2014; 33: 1-16 [PMID: 24346158 DOI: 10.1007/s10555-013-9455-3]
21. Hwang I. Cell-cell communication via extracellular membrane vesicles and its role in the immune response. Mol Cells 2013; 36: 105-111 [PMID: 23807045 DOI: 10.1007/s10059-013-0154-2]
22. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013; 91: 431-437 [PMID: 23519402 DOI: 10.1007/s00109-013-1020-6]
23. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15 Spec No 1: R17-R29 [PMID: 16651366]
24. Hüttenhofer A, Vogel J. Experimental approaches to identify non-coding RNAs. Nucleic Acids Res 2006; 34: 635-646 [PMID: 16436800]
25. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10: 155-159 [PMID: 19188922 DOI: 10.1038/nrg2521]
26. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23: 1494-1504 [PMID: 19571179 DOI: 10.1101/gad.1800909]
27. Eddy SR. Non-coding RNA genes and the modern RNA world. Nat Rev Genet 2001; 2: 919-929 [PMID: 11733745]
28. Ges teland RF, Cech TR, Atkins JF. The RNA World, 2nd ed. The Nature of Modern RNA Suggests a Prebiotic RNA World. New York: Cold Spring Harbor Laboratory Press, 1999: 49-77 [DOI: 10.1101/087969589.37.49]
29. Brosnan CA, Voinnet O. The long and the short of noncoding RNAs. Curr Opin Cell Biol 2009; 21: 416-425 [PMID: 19447594 DOI: 10.1016/j.ceb.2009.04.001]
30. Guan D, Zhang W, Zha ng W, Liu GH, Belmonte JC. Switching cell fate, ncRNAs coming to play. Cell Death Dis 2013; 4: e464 [PMID: 23328671 DOI: 10.1038/cddis.2012.196]
31. Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol 2014; 24: R762-R776 [PMID: 25137592 DOI: 10.1016/j.cub.2014.06.043]
32. Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 2013; 26: 155-165 [PMID: 22996375 DOI: 10.1038/modpathol.2012.160]
33. Horiuchi T, Aigaki T. Alternative trans-splicing: a novel mode of pre-mRNA processing. Biol Cell 2006; 98: 135-140 [PMID: 16417469]
34. Siomi MC, Sato K, Pezic D, Aravin AA. PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Biol 2011; 12: 246-258 [PMID: 21427766 DOI: 10.1038/nrm3089]
35. Dogini DB, Pascoal VD, Avansini SH, Vieira AS, Pereira TC, Lopes-Cendes I. The new world of RNAs. Genet Mol Biol 2014; 37: 285-293 [PMID: 24764762]
36. Bonfrate L,Altomare DF,Di Lena M,Travaglio E,Rotelli MT,De Luca A,Portincasa P. MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment J Gastrointestin Liver Dis 2013 22 311-320 PMID: 24078989]
37. Dong Y, Wu WK, Wu CW, Sung JJ, Yu J, Ng SS. MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br J Cancer 2011; 104: 893-898 [PMID: 21364594 DOI: 10.1038/bjc.2011.57]
38. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854 [PMID: 8252621]
39. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655 [PMID: 19239886 DOI: 10.1016/j.cell.2009.01.035]
40. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 2010; 1803: 1231-1243 [PMID: 20619301 DOI: 10.1016/j.bbamcr.2010.06.013]
41. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E, Filipowicz W. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005; 309: 1573-1576 [PMID: 16081698]
42. Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. Int J Genomics 2014; 2014: 970607 [PMID: 25180174 DOI: 10.1155/2014/970607]
43. Krol J, Loedige I, Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610 [PMID: 20661255 DOI: 10.1038/nrg2843]
44. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011; 1812: 592-601 [PMID: 21315819 DOI: 10.1016/j.bbadis.2011.02.002]
45. Ivey KN, Srivastava D. MicroRNAs as regulators of differentiation and cell fate decisions. Cell Stem Cell 2010; 7: 36-41 [PMID: 20621048 DOI: 10.1016/j.stem.2010.06.012]
46. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838 [PMID: 15944708]
47. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866 [PMID: 17060945]
48. Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K. Deep Sequencing the MicroRNA Transcrip tome in Colorectal Cancer. PLoS One 2013; 8: e66165 [PMID: 23824282]
49. Popadin K, Gutierrez-Arcelus M, Dermitzakis ET, Antonarakis SE. Genetic and epigenetic regulation of human lincRNA gene expression. Am J Hum Genet 2013; 93: 1015-1026 [PMID: 24268656 DOI: 10.1016/j.ajhg.2013.10.022]
50. Tahira AC, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS, Maracaja-Coutinho V, Verjovski-Almeida S, Machado MC, Reis EM. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer 2011; 10: 141 [PMID: 22078386 DOI: 10.1186/1476-4598-10-141]
51. Beltran M, Puig I, Peña C, García JM, Alvarez AB, Peña R, Bonilla F, de Herreros AG. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev 2008; 22: 756-769 [PMID: 18347095 DOI: 10.1101/gad.455708]
52. Song X, Wang X, Arai S, Kurokawa R. Promoter-Associated noncoding RNA from the CCND1 promoter. Methods Mol Biol 2012; 809: 609-622 [PMID: 22113303 DOI: 10.1007/978-1-61779-3 76-9-39]
53. Chan WL, Chang JG. Pseudogene-derived endogenous siRNAs and their function. Methods Mol Biol 2014; 1167: 227-239 [PMID: 24823781 DOI: 10.1007/978-1-4939-0835-6-15]
54. Peng JC, Shen J, Ran ZH. Transcribed ultraconserved region in human cancers. RNA Biol 2013; 10: 1771-1777 [PMID: 24384562 DOI: 10.4161/rna.26995]
55. Zhu JG, Shen YH, Liu HL, Liu M, Shen YQ, Kong XQ, Song GX, Qian LM. Long noncoding RNAs expression profile of the developing mouse heart. J C ell Biochem 2014; 115: 910-918 [PMID: 24375461 DOI: 10.1002/jcb.24733]
56. Sun J, Lin Y, Wu J. Long non-coding RNA expression profiling of mouse testis during postnatal development. PLoS One 2013; 8: e75750 [PMID: 24130740 DOI: 10.1371/journal.pone.0075750]
57. Kitagawa M,Kitagawa K,Kotake Y,Niida H,Ohhata T. Cell cycle regulation by long non-coding RNAs Cell Mol Life Sci 2013 70 4785-4794 PMID: 23880895 DOI: 10.1007/s00018-013-1423-0]
58. Hu W, Yuan B, Flygare J, Lodish HF. Long noncoding RNAmediated anti-Apoptotic activity in murine erythroid terminal differ entiation. Genes Dev 2011; 25: 2573-2578 [PMID: 22155924 DOI: 10.1101/gad.178780.111]
59. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Boz zoni I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011; 147: 358-369 [PMID: 22000014 DOI: 10.1016/j.cell.2011.09.028]
60. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest-And starvation-Associated repressor of the glucocorticoid receptor. Sci Signal 2010; 3: ra8 [PMID: 20124551 DOI: 10.1126/scisignal.2000 568]
61. Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A. Repression of the human dihydrofolate reductase gene by a noncoding interfering transcript. Nature 2007; 445: 666-670 [PMID: 1 7237763]
62. Brockdorff N. Noncoding RNA and Polycomb recruitment. RNA 2013; 19: 429-442 [PMID: 23431328]
63. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329: 689-693 [PMID: 20616235 DOI: 10.1126/science.1192002]
64. Zap pulla DC, Cech TR. RNA as a flexible scaffold for proteins: yeast telomerase and beyond. Cold Spring Harb Symp Quant Biol 2006; 71: 217-224 [PMID: 17381300]
65. Willingham AT, Orth AP, Batalo v S, Peters EC, Wen BG, Aza-Blanc P, Hogenesch JB, Schultz PG. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. Science 2005; 309: 1570-1573 [PMID: 16141075]
66. Luke B, Lingner J. TERRA: telomeric repeat-containing RNA. EMBO J 2009; 28: 2503-2510 [PMID: 19629047 DOI: 10.1038/emboj.2009.166]
67. Wilusz JE, Freier SM, Spector DL. 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell 2008; 135: 919-932 [PMID: 19041754 DOI: 10.1016/j.cell.2008.10.012]
68. Chan WL, Yuo CY , Yang WK, Hung SY, Chang YS, Chiu CC, Yeh KT, Huang HD, Chang JG. Transcribed pseudogene ?PPM1K generates endogenous siRNA to suppress oncogenic cell growth in hepatocellular carcinoma. Nucleic Acids Res 2013; 41: 3734-3747 [PMID: 23376929 DOI: 10.1093/nar/gkt047]
69. Liu T, Huang Y, Chen J, Chi H, Yu Z, Wang J, Chen C. Attenuated ability of BACE1 to cleave the amyloid precursor protein via silenci ng long noncoding RNA BACE1?AS expression. Mol Med Rep 2014; 10: 1275-1281 [PMID: 24970022 DOI: 10.3892/mmr.2014.2351]
70. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N. Circular RNAs are a large class of animal RNAs with regulatory potency. Natur e 2013; 495: 333-338 [PMID: 23446348 DOI: 10.1038/nature11928]
71. Luo H, Zhao X, Wan X, Huang S, Wu D. Gene microarray analysis of the lncRNA expression profile in human urothelial carcinoma o f the bladder. Int J Clin Exp Med 2014; 7: 1244-1254 [PMID: 24995079]
72. Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y, Fang G. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol 2013; 139: 437-445 [PMID: 23143645 DOI: 10.1007/s00432-012-1324-x]
73. Ganetzky B, Wu CF. Neurogenetics of membrane excitability in Drosophila. Annu Rev Genet 1986; 20: 13-44 [PMID: 2434020]
74. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-891 [PMID: 14573789]
75. Arndt GM, Dossey L, Cullen LM, Lai A, D ruker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A, Raponi M. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009 ; 9: 374 [PMID: 19843336 DOI: 10.1186/1471-2407-9-374]
76. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zh ang Y, Ren Z, Zen K, Zhang J, Zhang CY. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-1392 [PMID: 19137007 DOI: 10.1038/onc.2008.474]
77. Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med 2009; 1: 36 [PMID: 19341507 DOI: 10.1186/gm36]
78. Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 2006; 16: 845-850 [PMID: 16969504]
79. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, Jiang BH. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012; 40: 76 1-774 [PMID: 21917858 DOI: 10.1093/nar/gkr730]
80. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207-3212 [PMID: 19202062 DOI: 10.1073/pnas.0808042106]
81. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Ro ldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261 [PMID: 16461460]
82. Griffin CA, Hawkins AL, Packer RJ, Rorke LB, Emanuel BS. Chromosome abnormalities in pediatric brain tumors. Cancer Res 1988; 48: 175-180 [PMID: 3334992]
83. Wu G, Sinclair C, Hinson S, Ingle JN, Roche PC, Couch FJ. Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast ca ncer cell lines and tumors. Cancer Res 2001; 61: 4951-4955 [PMID: 11431322]
84. Löffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, Burger R, Grama tzki M, Blumert C, Bauer K, Cvijic H, Ullmann AK, Stadler PF, Horn F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Bl ood 2007; 110: 1330-1333 [PMID: 17496199]
85. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K, Iba H. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 2008; 378: 492-504 [PMID: 18384814 DOI: 10.1016/j.jmb.2008.03.015]
86. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE. miR-21: an androgen receptorregulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009; 69: 7165-7169 [PMID: 19738047 DOI: 10.1158/0008-5472. CAN-09-1448]
87. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-t ranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136 [PMID: 17968323]
88. Vicinus B, Rubie C, Faust SK, Frick VO, Ghadjar P, Wagner M, Graeber S, Schilling MK. miR-21 functionally interacts with the 3' UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells. Cancer Lett 2012; 316: 105-112 [PMID: 22099878 DOI: 10.1016/j.canlet.2011.10.031]
89. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ, Lazo JS, Wang Z, Zhang L, Yu J. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009; 69: 8157-8165 [PMID: 19826040 DOI: 10.1158/0008-5472. CAN-09-1996]
90. Roy S, Yu Y, Padhye SB, Sarkar FH, Majumdar AP. Difluorinatedcurcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One 2013; 8: e68543 [PMID: 23894315 DOI: 10.1371/journal.pone.0068543]
91. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Dav uluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27: 1859-1867 [PMID: 17194750]
92. Qu A, Du L, Yang Y, Liu H, Li J, Wang L, Liu Y, Dong Z, Zhang X, Jiang X, Wang H, Li Z, Zheng G, Wang C. Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PLoS One 2014 ; 9: e90952 [PMID: 24632577 DOI: 10.1371/journal.pone.0090952]
93. Ota T, Doi K, Fujimoto T, Tanaka Y, Ogawa M, Matsuzaki H, Kuroki M, Miyamoto S, Shirasawa S, Tsunoda T. KRAS upr egulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res 2012; 32: 2271-2275 [PMID: 22641662]
94. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY, Sun XF. Clinicopathological significance of microRNA-31,-143 and-145 expression in colorectal cancer. Dis Markers 2009; 26: 27-34 [PMID: 19242066 DOI: 10.3 233/DMA-2009-0601]
95. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinic opathologic features of colorectal cancer. Oncology 2007; 72: 397-402 [PMID: 18196926 DOI: 10.1159/000113489]
96. Li T, Luo W, Liu K, Lv X, Xi T. miR-31 promotes proliferation of colon cancer cells by targeting E2F2. Biotechnol Lett 2015; 37: 523-532 [PMID: 25362258 DOI: 10.1007/s10529-014-1715-y]
97. Yang MH, Yu J, Chen N, Wang XY, Liu XY, Wang S, Ding YQ. Elevated m icroRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS One 2013; 8: e85353 [PMID: 24386467 DOI: 10.1371/journal.pone.0085353]
98. Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J, Zhang CY, Chen J, Zhang J. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem 2 013; 288: 9508-9518 [PMID: 23322774 DOI: 10.1074/jbc.M112.367763]
99. Koga Y, Yasunaga M, Takahashi A, Kuroda J, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H, Matsumura Y. Mi croRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 2010; 3: 1435-1442 [PMID: 20959518 DOI: 10.1158/1940-6207.CAPR-10-0036]
100. Dews M, Homayouni A,Yu D,Murphy D,Sevignani C,Wentzel E,Furth EE,Lee WM,Enders GH,Mendell JT,Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-Activated microRNA cluster Nat Genet 2006 38 1060-1065 PMID: 16878133]
101. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous r oles in health and disease. Cell Death Differ 2013; 20: 1603-1614 [PMID: 24212931 DOI: 10.1038/cdd.2013.125]
102. Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 2013; 52: 459-474 [PMID: 22308110 DOI: 10.1002/mc.21879]
103. Humphreys KJ, McKinnon RA, Michael MZ. miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells. PLoS One 2014; 9: e112288 [PMID: 25379703 DOI: 10.1371/journal.pone.0112288]
104. Fujiya M, Konishi H, Mohamed Kamel MK, Ueno N, Inaba Y, Moriichi K, Tanabe H, Ikuta K, Ohtake T, Kohgo Y. microRNA-18a induces apoptosis in colon cancer cells via the autophagolysosomal degradation of oncogenic heterogeneous nuclear ribonucleoprotein A1. Oncogene 2014; 33: 4847-4856 [PMID: 24166503 DOI: 10.1038/onc.2013.429]
105. Stengel KR, Zheng Y. Essential role of Cdc42 in Ras-induced transformation revealed by gene targeting. PLoS One 2012; 7: e37317 [PMID: 22719838 DOI: 10.1371/journal.pone.0037317]
106. Reymond N, Im JH, Garg R, Vega FM, Borda d'Agua B, Riou P, Cox S, Va lderrama F, Muschel RJ, Ridley AJ. Cdc42 promotes transendothelial migration of cancer cells through ?1 integrin. J Cell Biol 2012; 199: 653-668 [PMID: 23148235 DOI: 10.1083/jcb.201205169]
107. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995; 81: 53-62 [PMID: 7536630]
108. Jér ǒme T, Laurie P, Louis B, Pierre C. Enjoy the Silence: The Story of let-7 MicroRNA and Cancer. Curr Genomics 2007; 8: 229-233 [PMID: 18645597]
109. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival . Cancer Res 2004; 64: 3753-3756 [PMID: 15172979]
110. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, Wood W, Becker KG, Morin PJ. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008; 3: e2436 [PMID: 18560586 DOI: 10.1371/journal. pone.0002436]
111. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006; 29: 903-906 [PMID: 16651716]
112. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol 2008; 18: 505-516 [PMID: 18774294 DOI: 10.1016/j.tcb.2008.07.007]
113. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647 [PMID: 15766527]
114. Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/-cetuximab. BMC Cancer 2012; 12: 534 [PMID: 23167843 D OI: 10.1186/1471-2407-12-534]
115. Chetty R, Govender D. Gene of the month: KRAS. J Clin Pathol 2013; 66: 548-550 [PMID: 23626007 DOI: 10.1136/jclinpath-2013-201663]
116. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460 [PMID: 20018966 DOI: 10.1056/NEJMra0804588]
117. Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Börger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman M, Meijer GA, van Krieken JH, Kuiper R, Punt CJ, Nagtegaal ID. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012; 12: 292 [PMID: 22804917 DOI: 10.1186/1471-2407-12-292]
118. Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, Guglielmino MR, Duro LR, Angelica R, Caltabiano R, Biondi A, Di Vita M, Privitera G, Scalia M, Cappellani A, Vasquez E, Lanzafame S, Basile F, Di Pietro C, Purrello M. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 201 0; 9: 3396-3409 [PMID: 20881268 DOI: 10.1158/1535-7163. MCT-10-0137]
119. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with c etuximab monotherapy. Ann Oncol 2011; 22: 104-109 [PMID: 20603437 DOI: 10.1093/annonc/mdq315]
120. Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brand t PA, Bosman FT, Weidhaas JB, van Engeland M. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 2011; 17: 7723-7731 [PMID: 21994416 DOI: 10.1158/1078-0432. CCR-11-0990]
121. Langevin SM,Christensen BC. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-Analysis Cancer Med 2014 3: 1385-1395 PMID: 24890702 DOI: 10.1002/cam4.279]
122. Han HB, Gu J, Zuo HJ, Chen ZG, Zhao W, Li M, Ji DB, Lu YY, Zhang ZQ. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol 2012; 226: 544-555 [PMID: 21984339 DOI: 10.1002/path.3014]
123. Ragusa M, Statello L, Maugeri M, Majorana A, Barbagallo D, Salito L, Sammito M, Santonocito M, Angelica R, Cavallaro A, Scalia M, Caltabiano R, Privitera G, Biondi A, Di Vita M, Cappellani A, Vasquez E, Lanzafame S, Tendi E, Celeste S, Di Pietro C, Basile F, Purrello M. Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. J Mol Med (Berl) 2012; 90: 1421-1438 [PMID: 22660396 DOI: 10.1007/s00109-012-0918-8]
124. Sheth SS, Bodnar JS, Ghazalpour A, Thipphavong CK, Tsutsumi S, Tward AD, Demant P, Kodama T, Aburatani H, Lusis AJ. Hepatocellular carcinoma in Txnip-deficient mice. Oncogene 2006; 25: 3528-3536 [PMID: 16607285]
125. Yamashita S, Yamamoto H, Mimori K, Nishida N, Takahashi H, Haraguchi N, Tanaka F, Shibata K, Sekimoto M, Ishii H, Doki Y, Mori M. MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncology 2012; 82: 205-212 [PMID: 22456107 DOI: 10.1159/000336809]
126. Wang X, Kuang Y, Shen X, Zhou H, Chen Y, Han Y, Yuan B, Zhou J, Zhao H, Zhi Q, Xue X. Evaluation of miR-720 prognostic significance in patients with colorectal cancer. Tumour Biol 2015; 36: 719-727 [PMID: 25286763 DOI: 10.1007/s13277-014-2697-z]
127. Nasrallah A, Saykali B, Al Dimassi S, Khoury N, Hanna S, El-Sibai M. Effect of StarD13 on colorectal cancer proliferation, motility and invasion. Oncol Rep 2014; 31: 505-515 [PMID: 24253896 DOI: 10.3892/or.2013.2861]
128. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett 2014; 344: 166-173 [PMID: 24262661 DOI: 10.1016/j.canlet.2013.11.004]
129. Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer 2013; 132: 745-754 [PMID : 22753312 DOI: 10.1002/ijc.27708]
130. Liu S, Tetzlaff MT, Cui R, Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol 2012; 181: 1823-1835 [PMID: 22982443 DOI: 10.1016/j.ajpath.2012.07.009]
131. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR, Goel A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer me tastasis. Gut 2013; 62: 1315-1326 [PMID: 22735571 DOI: 10.1136/gutjnl-2011-301846]
132. Lu YX, Yuan L, Xue XL, Zhou M, Liu Y, Zhang C, Li JP, Zheng L, Hong M, Li XN. Regulation of colorectal carcinoma stemness, growth, and metastasis by an miR-200c-Sox2-negative feedback loop mechanism. Clin Cancer Res 2014; 20: 2631-2642 [PMID: 24658157 DOI: 10.1158/1078-0432.CCR-13-2348]
133. Rokavec M, Ö ner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, Slotta-Huspenina J, Bader FG, Greten FR, Hermeking H. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorecta l cancer invasion and metastasis. J Clin Invest 2014; 124: 1853-1867 [PMID: 24642471 DOI: 10.1172/JCI73531]
134. Hahn S, Jackstadt R, Siemens H, Hünten S, Hermeking H. SNAIL and miR-34a f eed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. EMBO J 2013; 32: 3079-3095 [PMID: 24185900 DOI: 10.1038/emboj.2013.236]
135. Siemens H, Neumann J, Jacksta dt R, Mansmann U, Horst D, Kirchner T, Hermeking H. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and ?-catenin predicts distant metastasis of colon cancer. Clin Cancer Res 2013; 19: 710-720 [PMID: 23243217 DOI: 10.1158/1078-0432. CCR-12-1703]
136. Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, Hermeking H. miR-34 and SNAIL form a double-negati ve feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10: 4256-4271 [PMID: 22134354 DOI: 10.4161/cc.10.24.18552]
137. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA, Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008; 68: 5795-5802 [PMID: 18632633 DOI: 10.1158/0008-5472.CAN-08-0951]
138. Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, Veronese A, Fabbri M, Carasi S, Alder H, Lanza G, Gafa' R, Moyer MP, Ridgway RA, Cordero J, Nuovo GJ, Frankel WL, Rugge M, Fassan M, Groden J, Vogt PK, Karin M, Sansom OJ, Croce CM. MicroRNA-135b promotes cancer progression b y acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014; 25: 469-483 [PMID: 24735923 DOI: 10.1016/j.ccr.2014.03.006]
139. Xu XM, Qian JC, Deng ZL, Cai Z , Tang T, Wang P, Zhang KH, Cai JP. Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett 2012; 4: 339-345 [PMID: 22844381]
140. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R, Slaby O. Identification and functional screening of microRNAs highly dere gulated in colorectal cancer. J Cell Mol Med 2012; 16: 2655-2666 [PMID: 22469014 DOI: 10.1111/j.1582-4934.2012.01579.x]
141. Zhou W, Li X, Liu F, Xiao Z, He M, Shen S, Liu S. MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. Acta Biochim Biophys Sin (Shanghai) 2012; 44: 838-846 [PMID: 23017832]
142. Sun JY, Huang Y, Li JP, Zhang X, Wang L, Meng YL, Yan B, Bian YQ, Zhao J, Wang WZ, Yang AG, Zhang R. MicroRNA-320a suppresses human colon canc er cell proliferation by directly targeting ?-catenin. Biochem Biophys Res Commun 2012; 420: 787-792 [PMID: 22459450 DOI: 10.1016/j.bbrc.2012.03.075]
143. Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, Zhang Q, Dong L, Liu Y, Dong J. microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 2012; 27: 685-694 [P MID: 22134529 DOI: 10.3892/or.2011.1561]
144. Zhao H, Dong T, Zhou H, Wang L, Huang A, Feng B, Quan Y, Jin R, Zhang W, Sun J, Zhang D, Zheng M. miR-320a suppresses colorectal cancer progression by targeting Rac1. Carcinogenesis 2014; 35: 886-895 [PMID: 24265291 DOI: 10.1093/carcin/bgt378]
145. Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z, Xi J, Yan L, Gu J. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol Cancer 2014; 13: 86 [PMID: 24755295 DOI: 10.1186/1476-4598-13-86]
146. Wei Z, Cui L, Mei Z, Liu M, Zhang D. miR-181a mediates metabolic shift in colon cancer cells via the PTEN/AKT pathway. FEBS Lett 2014; 588: 1773-1779 [PMID: 24685694 DOI: 10.1016/j.febslet.2014.03.037]
147. Catela Ivkovic T, Aralica G, Cacev T, Loncar B, Kapitanovic S. miR-106a overexpression and pRB downregulation in sporadic colorectal cancer. Exp Mol Pathol 2013; 94: 148-154 [PMID: 23178825 DOI: 10.1016/j.yexmp.2012.11.002]
148. Chinnam M, Goodrich DW. RB1, development, and cancer. Curr Top Dev Biol 2011; 94: 129-169 [PMID: 21295686 DOI: 10.1016/B978-0-12-380916-2.00005-X]
149. Feng B, Dong TT, Wang LL, Zhou HM, Zhao HC, Dong F, Zheng MH. Colorectal cancer migrati on and invasion initiated by microRNA-106a. PLoS One 2012; 7: e43452 [PMID: 22912877]
150. Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, Madison BB, Po zzi A, Moon RT, Moses HL, Grady WM. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 2006; 66: 9837-9844 [PMID: 17047044]
151. Wang M, Zhang P, Li Y, Liu G, Zhou B, Zhan L, Zhou Z, Sun X. The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c ove rexpression in human colorectal cancer. Med Oncol 2012; 29: 3113-3118 [PMID: 22562822 DOI: 10.1007/s12032-012-0241-9]
152. Zhang GJ, Xiao HX, Tian HP, Liu ZL, Xia SS, Zhou T. Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med 2013; 31: 1375-1380 [PMID: 23588589 DOI: 10.3892/ijmm.2013.1348]
153. Pu J, Bai D, Yang X, Lu X, Xu L, Lu J. Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochem Biophys Res Commun 2012; 428: 210-215 [PMID: 23036199 DOI: 10.1016/j.bbrc.2012.09.126]
154. Singh AB, Sharma A, Smith JJ, Krishnan M, Chen X, Eschrich S, Washington MK, Yeatman TJ, Beauchamp RD , Dhawan P. Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology 2011; 141: 2140-2153 [PMID: 21878201 DOI: 10.1053/j.gastro.2011.08.038]
155. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-2855 [PMID: 15837998]
156. Chell S, Kaidi A, Williams AC, Par askeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 2006; 1766: 104-119 [PMID: 16859832]
157. Misron NA, Looi LM, Nik Mustapha NR. Cyclooxygenase-2 expression in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression. Asian Pac J Cancer Prev 2015; 16: 1553-1558 [PMID: 25743830]
158. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, Spisni E, Pantaleo MA, Biasco G, Tomasi V. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009; 315: 1439-1447 [PMID: 19133256 DOI: 10.1016/j.yexcr.2008.12.010]
159. Ruan D, So SP. Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo. Life Sci 2014; 116: 43-50 [PMID: 25139833 DOI: 10.1016/j.lfs.2014.07.042]
160. Strillacci A, Valerii MC, Sansone P, Caggiano C, Sgromo A, Vittori L, Fiorentino M, Poggioli G, Rizzello F, Campieri M, Spisni E. Loss of miR-101 expression promotes Wnt/ ?-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol 2013; 229: 379-389 [PMID: 22930392 DOI: 10.1002/path.4097]
161. Chandramouli A, Onyeagucha BC, Mercado-Pimentel M E, Stankova L, Shahin NA, LaFleur BJ, Heimark RL, Bhattacharyya AK, Nelson MA. MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther 2012; 13: 175-183 [PMID: 22353936 DOI: 10.4161/cbt.13.3.18874]
162. Ma K, Pan X, Fan P, He Y, Gu J, Wang W, Zhang T, Li Z, Luo X. Loss of miR-638 in vitro promotes cell invasion and a mesenchymalli ke transition by influencing SOX2 expression in colorectal carcinoma cells. Mol Cancer 2014; 13: 118 [PMID: 24885288 DOI: 10.1186/1476-4598-13-118]
163. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, Bamlet WR, de Narvajas AA, Gomez TS, Simeone DM, Bujanda L, Billadeau DD. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013; 2: e61 [PMID: 23917223 DOI: 10.1038/oncsis.2013.23]
164. Zhang J,Fei B,Wang Q,Song M,Yin Y,Zhang B,Ni S,Guo W,Bian Z,Quan C,Liu Z,Wang Y,Yu J,Du X,Hua D,Huang Z. MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma Oncotarget 2014 5 12083-12096 PMID: 25301729]
165. Chen L, Yuan D, Zhao R, Li H, Zhu J. Suppression of TSPAN1 by RNA interference inhibits proliferation and invasion of colon cancer cells in vitro. Tumori 2010; 96: 744-750 [PMID: 21302622]
166. Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, Comoglio PM, Columbano A, Giordano S. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res 2012; 18: 737-747 [PMID: 22179665 DOI: 10.1158/1078-0432. CCR-11-1699]
167. Zhang H, Hao Y, Yang J, Zhou Y, Li J, Yin S, Sun C, Ma M, Huang Y, Xi JJ. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun 2011; 2: 554 [PMID: 22109528 DOI: 10.1038/ncomms155 5]
168. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently los t in colon cancers. Genes Chromosomes Cancer 2008; 47: 939-946 [PMID: 18663744 DOI: 10.1002/gcc.20596]
169. Zhou Y, Feng X, Liu YL, Ye SC, Wang H, Tan WK, Tian T, Qiu YM, Luo H S. Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways. PLoS One 2013; 8: e81203 [PMID: 24312276 DOI: 10.1371/journal.p one.0081203]
170. Liu Y, Zhou Y, Feng X, An P, Quan X, Wang H, Ye S, Yu C, He Y, Luo H. MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signaling pathw ays. Int J Oncol 2014; 44: 203-210 [PMID: 24189753 DOI: 10.3892/ijo.2013.2168]
171. Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, Zhou J, Hu J, Jiang B. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep 2013; 30: 1976-1984 [PMID: 23900443 DOI: 10.3892/or.2013.2633]
172. Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H, Lai M. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ 2011; 18: 1702-1710 [PMID: 21455217 DOI: 10.1038/cdd.2011.28]
173. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, Liu Z. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg 2010; 14: 1170-1179 [PMID: 20422307 DOI: 10.1007/s11605-010-1202-2]
174. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22: 8031-8041 [PMID: 12970751]
175. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM, Zheng SS. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012; 29: 1810-1816 [PMID: 21678027 DOI: 10.1007/s12032-011-0004-z]
176. Yamada K, Kano J, Tsunoda H, Yoshikawa H, Okubo C, Ishiyama T, Noguchi M. Phenotypic characterizat ion of endometrial stromal sarcoma of the uterus. Cancer Sci 2006; 97: 106-112 [PMID: 16441420]
177. Hutchinson JN, Ensminger AW, Clemson CM, Lynch CR, Lawrence JB, Chess A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 2007; 8: 39 [PMID: 17270048]
178. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007; 26: 851-858 [PMID: 16878148]
179. Garen A, Song X. Regulatory roles of tumor-suppressor proteins and noncoding RNA in cancer and normal cell functions. Int J Cancer 2008; 122: 1687-1689 [PMID: 18067128]
180. Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein J D, Dorrestein PC, Rosenfeld MG. ncRNA-And Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 2011; 147: 773-788 [PMID: 22078878 DOI: 10.1016/j.cell.2011.08.054]
181. Ying L, Chen Q, Wang Y, Zhou Z, Huang Y, Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 2012; 8: 2289-2294 [PMID: 22722759]
182. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, Prasanth KV. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010; 39: 925-938 [PMID: 20797886 DOI: 10.1016/j.molcel.2010.08.011]
183. Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol 2011; 39: 169-175 [PMID: 21503572 DOI: 10.3892/ijo.2011.1007]
184. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritch a rd-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R , Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954 [PMID: 12068308]
185. Guo Q,Zhao Y,Chen J,Hu J,Wang S,Zhang D,Sun Y. BRAFactivated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition Oncol Lett 2014 8 869-875 PMID: 25013510]
186. Grisanzio C, Freedman ML. Chromosome 8q24-Associated Cancers and MYC. Genes Cancer 2010; 1: 555-559 [PMID: 21779458 DOI: 10.1177/1947601910381380]
187. Huppi K, Pitt JJ, Wahlberg BM, Caplen NJ. The 8q24 gene desert: an oasis of non-coding transcriptional activity. Front Genet 2012; 3: 69 [PMID: 22558003 DOI: 10.3389/fgene.2012.00069]
188. Haiman CA, Le Marchand L, Yamamato J, Stram DO, Sheng X, Kolonel LN, Wu AH, Reich D, Henderson BE. A common genetic risk factor for colorectal and prostate cancer. Nat Genet 2007; 39 : 954-956 [PMID: 17618282]
189. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Hai man CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML. The 8q24 cancer risk variant rs6983267 shows long-range in teraction with MYC in colorectal cancer. Nat Genet 2009; 41: 882-884 [PMID: 19561607 DOI: 10.1038/ng.403]
190. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Björklund M, Wei G, Yan J, Niittymäki I, Mecklin JP, Järvinen H, Ristimäki A, Di-Bernardo M, East P, Carvajal-Carmona L, Houlston RS, Tomlinson I, Palin K, Ukkonen E, Karhu A, Taipale J, Aaltone n LA. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009; 41: 885-890 [PMID: 19561604 DOI: 10.1038/ng.406]
191. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafá R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopet z S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 2013; 23: 1446-1461 [PMID: 23796952 DOI: 10.1101/gr.152942 .112]
192. Nissan A, Stojadinovic A, Mitrani-Rosenbaum S, Halle D, Grinbaum R, Roistacher M, Bochem A, Dayanc BE, Ritter G, Gomceli I, Bostanci EB, Akoglu M, Chen YT, Old LJ, Gure AO. Colon cancer associated transcript-1: a novel RNA expressed in malignant and premalignant human tissues. Int J Cancer 2012; 130: 1598-1606 [PMID: 21547902 DOI: 10.1002/ijc.26170]
193. Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, Zhang S, Wang HB, Ge J, Lu X, Yang L, Chen LL. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Re s 2014; 24: 513-531 [PMID: 24662484 DOI: 10.1038/cr.2014.35]
194. Beck-Engeser GB, Lum AM, Huppi K, Caplen NJ, Wang BB, Wabl M. Pvt1-encoded microRNAs in oncogenesis. Retrov irology 2008; 5: 4 [PMID: 18194563 DOI: 10.1186/1742-4690-5-4]
195. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadn ell TC, Essig J, Otto GM, O'Sullivan MG, Largaespada DA, Schwertfeger KL, Marahrens Y, Kawakami Y, Bagchi A. PVT1 dependence in cancer with MYC copy-number increase. Nature 2014; 512: 82-86 [P MID: 25043044 DOI: 10.1038/nature13311]
196. Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-Dependent induction of PVT1 and miR-1204. J Biol Chem 2012; 287: 2509-2519 [ PMID: 22110125 DOI: 10.1074/jbc. M111.322875]
197. Wu Y, Zhang L, Wang Y, Li H, Ren X, Wei F, Yu W, Wang X, Zhang L, Yu J, Hao X. Long noncoding RNA HOTAIR involvement in cancer. Tumour Biol 2014; 35: 9531-9538 [PMID: 25168368 DOI: 10.1007/s13277-014-2523-7]
198. Li L, Liu B, Wapinski OL, Tsai MC, Qu K, Zhang J, Carlson JC, Lin M, Fang F, Gupta RA, Helms JA, Chang HY. Targeted disruption of Hotair leads to homeotic transformation and gene derepression. Cell Rep 2013; 5: 3-12 [PMID: 24075995 DOI: 10.1016/j.celrep.2013.09.003]
199. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY. Long noncoding RNA HO TAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-1076 [PMID: 20393566 DOI: 10.1038/nature08975]
200. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71: 6320-6326 [PMID: 21862635 DOI: 10.1158/0008-5472.CAN-11-1021]
201. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES, Rinn JL. Many human large intergenic noncod ing RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106: 11667-11672 [PMID: 19571010 DOI: 10.1073/pnas.0904715106]
202. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, Regev A, Rinn JL, Root DE, Lander ES. lincRNAs act in the circuitry controlling pluripotenc y and differentiation. Nature 2011; 477: 295-300 [PMID: 21874018 DOI: 10.1038/nature10398]
203. Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, Wu F, Mo YY. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res 2013; 41: 4976-4987 [PMID: 23558749 DOI: 10. 1093/nar/gkt182]
204. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007; 2: e845 [ PMID: 17786216]
205. Lustig O, Ariel I, Ilan J, Lev-Lehman E, De-Groot N, Hochberg A. Expression of the imprinted gene H19 in the human fetus. Mol Reprod Dev 1994; 38: 239-246 [PMID: 7917273]
206. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002; 62: 6442-644 6 [PMID: 12438232]
207. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, Kwok TT. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010; 31: 350-358 [PMID: 19926638 DOI: 10.1093/carcin/bgp181]
208. Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, Lu L, Liu C, Yi JS, Zhang H, Min W, Bennett AM, Gregory RI, Ding Y, Huang Y. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell 2013; 52: 101-112 [PMID: 24055342 DOI: 10.1016/j.molcel.2013.08.027]
209. Rigoutsos I, Lee SK, Nam S Y, Ivkovic TC, Pichler M, Rossi S, Clark P, Yi J, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafa R, Spizzo R, Nicoloso M, Shariati M, T iron A, Yeh JJ, Teruel R, Melo S, Xiao L, Flores ER, Negrini M, Bar-Eli M, Mani S, Liu CG, Berindan-Neagoe I, Esteller M, Keating M, Lanza G, Calin G. N-BLR, a primate-specific noncoding transcr i pt, modulates the epithelial-to-mesenchymal transition and leads to colorectal cancer invasion and migration. Available from: URL: http://biorxiv.org/content/early/2014/05/06/004796
210. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 2012; 7: e30733 [PMID: 22319583 DOI: 10.1371/journal.pone.0030733]
211. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature 2013; 495: 384-388 [PMID: 23446346 DOI: 10.1038/nat ure11993]
212. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res 2013; 73: 5609-5612 [PMID: 24014594 DOI: 10.1158/0008-5472.CAN-13-1568]
213. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeillinger R, Pils D. Correlation of circular RNA abundance with proliferation-exemplified with col orectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. Sci Rep 2015; 5: 8057 [PMID: 25624062 DOI: 10.1038/srep08057]
214. Cekaite L, Rantala JK, Bruun J, Guriby M, Age sen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI. MiR-9,-31, and-182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012; 14: 868-87 9 [PMID: 23019418]
215. Nielsen BS, Jørgensen S, Fog JU, Søkilde R, Christensen IJ, Hansen U, Brünner N, Baker A, Møller S, Nielsen HJ. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011; 28: 27-38 [PMID: 21069438 DOI: 10.1007/s10585-010-9355-7]
216. Kang WK, Lee JK, Oh ST, Lee SH, Jung CK. Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse. BMC Gastroenterol 2015; 15 : 2 [PMID: 25609245]
217. Vickers MM, Bar J, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ, Maroun J, Lorimer IA, Goss GD, Dimitroulako s J. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis 2012; 29: 123-132 [PMID: 22120473 DOI: 10.1007/s10585-011-9435-3]
218. Díaz R, Silva J, García JM, Lorenzo Y, García V, Peña C, Rodríguez R, Muñoz C, García F, Bonilla F, Domínguez G. Deregulated expression of miR-106a predicts survival in human colon ca ncer patients. Genes Chromosomes Cancer 2008; 47: 794-802 [PMID: 18521848 DOI: 10.1002/gcc.20580]
219. Yin J, Bai Z, Song J, Yang Y, Wang J, Han W, Zhang J, Meng H, Ma X, Y ang Y, Wang T, Li W, Zhang Z. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin J Cancer Res 2014; 26: 95-103 [ PMID: 24653631 DOI: 10.3978/j.issn.1000-9604. 2014.02.07]
220. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ, Kruhøffer M, Laurberg S , Kauppinen S, Orntoft TF, Andersen CL. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-6424 [PMID: 18676867 DOI: 10.1158/0008-5472. CAN-07-6110]
221. Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, Lax S, Samonigg H, Hoefler G. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Patho l 2014; 67: 198-203 [PMID: 24098024 DOI: 10.1136/jclinpath-2013-201904]
222. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J. Non-coding Micro RNAs hsa-let-7g and hsamiR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics 2006; 3: 317-324 [PMID: 18172508]
223. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M, Ju J. Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights 2006; 2: 113-121 [PMID: 18079988]
224. Yu G, Tang JQ, Tian ML, Li H, Wang X, Wu T, Zhu J, Huang SJ, Wan YL. Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer. J Surg Oncol 2012; 106: 232-237 [PMID: 22065543 DOI: 10.1002/jso.22138]
225. 25 Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H, Allison RR. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof o f principle. Cancer Genomics Proteomics 2013; 10: 93-113 [PMID: 23741026]
226. Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, Naziri W, Marcuard SP. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2006; 6: 281-295 [PMID: 19996134]
227. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, Goel A. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1766-1774 [PMID: 20551304 DOI: 10.1158/1055-9965.EPI-10-0027]
228. Koga Y,Yamazaki N,Yamamoto Y,Yamamoto S,Saito N,Kakugawa Y,Otake Y,Matsumoto M,Matsumura Y. Fecal miR-106a is a useful marker for colorectal cancer patients with falsenegati ve results in immunochemical fecal occult blood test Cancer Epidemiol Biomarkers Prev 2013 22 1844-1852 PMID: 23950216 DOI: 10.1158/1055-9965.EPI-13-0512]
229. Yau TO, Wu CW, Dong Y, Tang CM, Ng SS, Chan FK, Sung JJ, Yu J. microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Canc er 2014; 111: 1765-1771 [PMID: 25233396 DOI: 10.1038/bjc.2014.484]
230. Wu CW, Ng SC, Dong Y, Tian L, Ng SS, Leung WW, Law WT, Yau TO, Chan FK, Sung JJ, Yu J. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res 2014; 20: 2994-3002 [PMID: 24691020 DOI: 10.1158/1078-0432.CCR-13-1750]
231. Hu Y, Chen HY, Yu CY, Xu J, Wang JL, Qian J, Zhang X, Fang JY. A long non-coding RNA signature to improve prognosis prediction of colorectal cancer. Oncotarget 2014; 5: 2230-2242 [PMID: 24809982]
232. Nagaraj SH, Reverter A. A Boolean-based systems biology approach to predict novel genes associated with cancer: Application to colorectal cancer. BMC Syst Biol 2011; 5: 35 [PMID: 2135255 6 DOI: 10.1186/1752-0509-5-35]
233. Graham LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, Vizgoft EK, Dunne R, Pimlott L, Young GP, Lapointe LC, Molloy PL. Colorectal Ne oplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. Genes Cancer 2011; 2: 829-840 [PMID: 22393467 DOI: 10.1177/1947601911431081]
234. Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX, Cai SJ. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol 2014; 7: 3174-3181 [PMID: 25031737]
235. Deng Q, He B, Gao T, Pan Y, Sun H, Xu Y, Li R, Ying H, Wang F, Liu X, Chen J, Wang S. Up-regulation of 91H promotes tumor meta stasis and predicts poor prognosis for patients with colorectal cancer. PLoS One 2014; 9: e103022 [PMID: 25058480 DOI: 10.1371/journal.pone.0103022]
236. You L, Chang D, Du HZ, Zhao YP. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. Biochem Biophys Res Commun 2011; 407: 1-6 [PMID: 21316338 DOI: 10.1016/j.bbrc.2011.02.027]
237. Al varez ML, DiStefano JK. Functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy. PLoS One 2011; 6: e18671 [PMID: 21526116 DOI: 10.1371/journal.pone.0018671]
238. Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Amplification of PVT-1 is involved in poor prog nosis via apoptosis inhibition in colorectal cancers. Br J Cancer 2014; 110: 164-171 [PMID: 24196785 DOI: 10.1038/bjc.2013.698]
239. Yu M, Ohira M, Li Y, Niizuma H, Oo ML, Zhu Y, Ozaki T, Isogai E, Nakamura Y, Koda T, Oba S, Yu B, Nakagawara A. High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol 200 9; 34: 931-938 [PMID: 19287950]
240. Zhu Y, Yu M, Li Z, Kong C, Bi J, Li J, Gao Z, Li Z. ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and sur vival. Urology 2011; 77: 510.e1-510. e5 [PMID: 21147498 DOI: 10.1016/j.urology.2010.09.022]
241. Qi P, Xu MD, Ni SJ, Shen XH, Wei P, Huang D, Tan C, Sheng WQ, Zhou XY, Du X. Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. Mol Carcinog 2015; 54: 742-750 [PMID: 24 519959 DOI: 10.1002/mc.22137]
242. Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H, Jia W. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol 2013; 30: 588 [PMID: 23640607 DOI: 10.1007/s12032-013-0588-6]
243. Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer 2013; 12: 261-266 [PMID: 24012455 DOI: 10.1016/j.clcc.2013.06.003]
244. Alaiyan B, Ilyayev N, Stojadinovic A, Izadjoo M, Roistacher M, Pavlov V, Tzivin V, Halle D, Pan H, Trink B, Gure AO, Nissan A. Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence. BMC Cancer 2013; 13: 196 [PMID: 23594791 DOI: 10.1186/1471-2407-13-196]
245. Braconi C, Valeri N, Kogure T, Gasparini P, Huang N, Nuovo GJ, Terracciano L, Croce CM, Patel T. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Pr oc Natl Acad Sci USA 2011; 108: 786-791 [PMID: 21187392 DOI: 10.1073/pnas.1011098108]
246. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, C roce CM. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007; 12: 215-229 [PMID: 17785203]
247. Sana J, Hankeova S, Svoboda M, Kiss I, Vyzula R, Slaby O. Expression levels of transcribed ultraconserved regions uc.73 and uc.388 are altered in colorectal cancer. Oncology 2012; 82: 114-118 [PMID: 22328099 DOI: 10.1159/000336479]
248. Pas ic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, Novokmet A, Malkin D. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q 13.31 in osteosarcoma. Cancer Res 2010; 70: 160-171 [PMID: 20048075 DOI: 10.1158/0008-5472. CAN-09-1902]
249. Qi P,Xu MD,Ni SJ,Huang D,Wei P,Tan C,Zhou XY,Du X. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer J Transl Med 2013 11 122 PMID: 23680400 DOI: 10.1186/1479-5876-11-122]
250. Shi D, Zheng H, Zhuo C, P eng J, Li D, Xu Y, Li X, Cai G, Cai S. Low expression of novel lncRNA RP11-462C24.1 suggests a biomarker of poor prognosis in colorectal cancer. Med Oncol 2014; 31: 31 [PMID: 24908062 DOI: 10.1007/s12032-01 4-0031-7]
251. Han J, Rong LF, Shi CB, Dong XG, Wang J, Wang BL, Wen H, He ZY. Screening of lymph nodes metastasis associated lncRNAs in colorectal cancer patients. World J Gastroenterol 2014; 20: 8139-8150 [PMID: 25009386 DOI: 10.3748/wjg.v20.i25.8139]
252. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, T rauner M, Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007; 132: 330-342 [PMID: 17241883]
253. Cui M, Zheng M, Sun B, Wang Y, Ye L, Zhang X. A long noncoding RNA perturbs the circadian rhythm of hepatoma cells to facilitate hepatocarcinogenesis. Neoplasia 2015; 17: 79-88 [PMID: 25622901 DOI: 10.1016/j.neo.2014.11.004]
254. Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweik H, Akkawi M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastr oenterol Hepatol 2009; 21: 688-692 [PMID: 19445043]
255. Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil i n vitro. Pharmacol Res 2007; 56: 248-253 [PMID: 17702597]
256. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM. MicroRNA-143 reduces viability and increases sensi tivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 2009; 276: 6689-6700 [PMID: 19843160 DOI: 10.1111/j.1742-4658.2009.07383.x]
257. Svoboda M, Izakovicova Holla L, Sefr R, Vrtkova I, Kocakova I, Tichy B, Dvorak J. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol 2008; 33: 541-547 [PMID: 18695884]
258. Hansen TF, Sø rensen FB, Lindebjerg J, Jakobsen A. The predictive value of microRNA-126 in relation to first line treatment with capecitabine an d oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 2012; 12: 83 [PMID: 22397399 DOI: 10.1186/1471-2407-12-83]
259. Drebber U, Lay M, Wedemeyer I, Vallböhmer D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP, Odenthal M. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol 2011; 39: 409-415 [PMID: 21567082 DOI: 10.3892/ijo.2011.1036]
260. Fang L, Li H, Wang L, Hu J, Jin T, Wang J, Yang BB. MicroRNA-17-5p promotes chemotherap eutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014; 5: 2974-2987 [PMID: 24912422]
261. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S, Pepe S. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer . Int J Radiat Oncol Biol Phys 2012; 83: 1113-1119 [PMID: 22172905 DOI: 10.1016/j.ijrobp.2011.09.030]
262. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R, Slaby O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012; 7: 195 [PMID: 23167930 DOI: 10.1186/174 8-717X-7-195]
263. Hotchi M, Shimada M, Kurita N, Iwata T, Sato H, Morimoto S, Yoshikawa K, Higashijima J, Miyatani T. microRNA expression is able to predict response to chemoradiotherapy in rect al cancer. Mol Clin Oncol 2013; 1: 137-142 [PMID: 24649136]
264. Tsang WP, Wong TW, Cheung AH, Co CN, Kwok TT. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA 2007; 13: 890-898 [PMID: 17416635]
265. Lee H, Kim C, Ku JL, Kim W, Yoon SK, Kuh HJ, Lee JH, Nam SW, Lee EK. A long non-coding RNA snaR contribute s to 5-fluorouracil resistance in human colon cancer cells. Mol Cells 2014; 37: 540-546 [PMID: 25078450 DOI: 10.14348/molcells.2014.0151]
266. Ma Y, Yang Y, Wang F, Moyer MP, Wei Q, Zhang P, Yang Z, Liu W, Zhang H, Chen N, Wang H, Wang H, Qin H. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/?-catenin signalling pathway via suppression of activator protein 2?. Gut 2015; Epub ahead of print [PMID: 25994219 DOI: 10.1136/gutjnl-2014-308392]
267. Boni V, Zarate R, Villa JC, Bandrés E, Gomez MA, Maiello E, Garcia-Foncillas J, Aranda E. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 2011; 11: 429-436 [PMID: 20585341 DOI: 10.1038/tpj.2010.58]
268. Xing J, Wan S, Zhou F, Qu F, Li B, Myers RE, Fu X, Palazzo JP, He X, Chen Z, Yang H. Genetic polymorphisms in pre-microRNA g enes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 217-227 [PMID: 22028396 DOI: 10.1158/1055-9965.EPI-11-0624]
269. Lin M, Gu J, Eng C, Ellis LM , Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer R es 2012; 18: 3982-3991 [PMID: 22661538 DOI: 10.1158/1078-0432. CCR-11-2951]
270. Min KT, Kim JW, Jeon YJ, Jang MJ, Chong SY, Oh D, Kim NK. Association of the miR-146aC& g t; G, 149C& gt; T, 196a2C& gt; T, and 499A& gt; G polymorphisms with colorectal cancer in the Korean population. Mol Carcinog 2012; 51 Suppl 1: E65-E73 [PMID: 22161766 DOI: 10.1002/mc.21849]
271. Zhan JF, Chen LH, Chen ZX, Yuan YW, Xie GZ, Sun AM, Liu Y. A functional variant in microRNA-196a2 is associated with susceptibility of colorectal cancer in a Chinese population. Arch Med Res 2011; 42: 144-148 [PMID: 21565628 DOI: 10.1016/j.arcmed.2011.04.001]
272. Chen H, Sun LY, Chen LL, Zheng HQ, Zhang QF. A variant in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese. Intern Med J 2012; 42: e115-e119 [PMID: 21241442 DOI: 10.1111/j.1445-5994.2011.02434.x]
273. Wang Z, Sun X, Wang Y, Liu X, Xuan Y, Hu S. A ssociation between miR-27a genetic variants and susceptibility to colorectal cancer. Diagn Pathol 2014; 9: 146 [PMID: 25078482 DOI: 10.1186/1746-1596-9-146]
274. Hezova R, Kovarikova A, Bienertov a-Vasku J, Sachlova M, Redova M, Vasku A, Svoboda M, Radova L, Kiss I, Vyzula R, Slaby O. Evaluation of SNPs in miR-196-A2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol 2012 ; 18: 2827-2831 [PMID: 22719192 DOI: 10.3748/wjg.v18.i22.2827]
275. Li L, Sun R, Liang Y, Pan X, Li Z, Bai P, Zeng X, Zhang D, Zhang L, Gao L. Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer. J Exp Clin Cancer Res 2013; 32: 104 [PMID: 24330491 DOI: 10.1186/1756-99 66-32-104]
276. Khoury S, Tran N. Circulating microRNAs: potential biomarkers for common malignancies. Biomark Med 2015; 9: 131-151 [PMID: 25689901 DOI: 10.2217/bmm.14.102]
277. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadj anyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518 [PMID: 18663219 DOI: 10.1073/pnas.0804549105]
278. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zh ang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]
279. Zhang J, Li S, Li L, Li M, Guo C, Yao J, Mi S. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics 2015; 13: 17-24 [PMID: 25724326 DOI: 10.1016/j.gpb.2015.02.001]
280. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-7233 [PMI D: 21609964 DOI: 10.1093/nar/gkr254]
281. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cell s. Nat Cell Biol 2007; 9: 654-659 [PMID: 17486113]
282. Février B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004; 16: 415-421 [PMID: 15261674]
283. Théry C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Molecular characterization of dendritic cell-derived exosomes. Sel ective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147: 599-610 [PMID: 10545503]
284. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like ves icles are present in human blood plasma. Int Immunol 2005; 17: 879-887 [PMID: 15908444]
285. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 2004; 101: 13368-13373 [PMID: 15326289]
286. Andre F , Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L. Malignant effusions and immunogen ic tumour-derived exosomes. Lancet 2002; 360: 295-305 [PMID: 12147373]
287. Guduric-Fuchs J, O'Connor A, Camp B, O'Neill CL, Medina RJ, Simpson DA. Selective extracellular vesicle-medi ated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics 2012; 13: 357 [PMID: 22849433 DOI: 10.1186/1471-216 4-13-357]
288. Ragusa M, Barbagallo C, Statello L, Caltabi ano R, Russo A, Puzzo L, Avitabile T, Longo A, Toro MD, Barbagallo D, Valadi H, Di Pietro C, Purrello M, Reibaldi M. miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Patho logical and diagnostic implications. Cancer Biol Ther 2015; 16: 1387-1396 [PMID: 25951497]
289. Ragusa M, Statello L, Maugeri M, Barbagallo C, Passanisi R, Alhamdani MS, Li Destri G, Cappellani A, Barbagallo D, Scalia M, Valadi H, Hoheisel JD, Di Pietro C, Purrello M. Highly skewed distribution of miRNAs and proteins between colorectal cancer cells and their exosomes following Cetuximab treatment: biomol ecular, genetic and translational implications. Oncoscience 2014; 1: 132-157 [PMID: 25594007]
290. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol 2009; 11: 1143-1149 [PMID: 19684575 DOI: 10.1038/ncb1929]
291. Villarroya-Beltri C, Guti érrez-Vázquez C, Sánchez-Cabo F, Pérez-Hernández D, Vázquez J, Martin-Cofreces N, Martinez-Herrera DJ, Pascual-Montano A, Mittelbrunn M, Sánchez-Madrid F. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun 2013; 4: 2980 [PMID: 24356509 DOI: 10.1038/ncomms3980]
292. Cortez MA,Bueso-Ramos C,Ferdin J,Lopez-Berestein G,Sood AK,Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers Nat Rev Clin Oncol 2011 8-477 PMID: 21647195 DOI: 10.1038/nrclinonc.2011.76]
293. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008 [PMID: 21383194 DOI: 10.1073/pnas.1019055108]
294. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells b y high-density lipoproteins. Nat Cell Biol 2011; 13: 423-433 [PMID: 21423178 DOI: 10.1038/ncb2210]
295. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21 [PMID: 18589210 DOI: 10.1016/j.ygyno.2008.04.033]
296. Rabinowits G, Gerç el-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10: 42-46 [PMID: 19289371 DOI: 10.3816/CLC.2009.n.006]
297. Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 2014; 5: 9650-9663 [PMID: 25333260]
298. Silva J, Garcia V, Rodriguez M, Compte M, Cisneros E, Veguillas P, Garcia JM, Dominguez G, Campos-Martin Y, Cuevas J, Peña C, Herrera M, Diaz R, Mohammed N, Bonilla F. Analysis of exosome r elease and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer 2012; 51: 409-418 [PMID: 22420032]
299. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, Kohno T, Tsuchiya N. Circulating exo somal microRNAs as biomarkers of colon cancer. PLoS One 2014; 9: e92921 [PMID: 24705249 DOI: 10.1371/journal.pone.0092921]
300. Deng ZB, Zhuang X, Ju S, Xiang X, Mu J, Liu Y, Jiang H, Zhang L, Mobley J, McClain C, Feng W, Grizzle W, Yan J, Miller D, Kronenberg M, Zhang HG. Exosome-like nanoparticles from intestinal mucosal cells carry p rostaglandin E2 and suppress activation of liver NKT cells. J Immunol 2013; 190: 3579-3589 [PMID: 23467936 DOI: 10.4049/jimmunol.1203170]
301. Ragusa M, Barbagallo D, Purrello M. Exosomes: nanoshuttles to the future of BioMedicine. Cell Cycle 2015; 14: 289-290 [PMID: 25616496 DOI: 10.1080/15384101.2015.1006535]
302. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381 [PMID: 19201770 DOI: 10.1136/gut.2008.167817]
303. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 11 8-126 [PMID: 19876917 DOI: 10.1002/ijc.25007]
304. Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang L, Huang D, Tan C, Sheng W, Du X. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 2012; 7: e44398 [PMID: 22970209 DOI: 10.1371/journal.pone.0044398]
305. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorec tal liver metastasis. Cancer Epidemiol 2012; 36: e61-e67 [PMID: 22018950 DOI: 10.1016/j.canep.2011.05.002]
306. Giráldez MD, Lozano JJ, Ramírez G, Hijona E, Bujanda L, Castells A, Gironella M. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol 2013; 11: 681-8.e3 [PMID: 23267864 DOI: 10.1016/j.cgh.2012.12.009]
307. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cance r and predicts poor prognosis. PLoS One 2011; 6: e17745 [PMID: 21445232 DOI: 10.1371/journal.pone.0017745]
308. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010; 25: 1674-1680 [PMID: 20880178 DOI: 10.1111/j.1440-1746.2010.06417.x]
309. Chen J, Wang W, Zhang Y, Chen Y, Hu T. Predicting distant metastasis and chemoresistance using plasma miRNAs. Med Oncol 2014; 31: 79 9 [PMID: 24310813 DOI: 10.1007/s12032-013-0799-x]
310. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012; 256: 544-551 [PMID: 22868372 DOI: 10.1097/SLA.0b013e318265bd6f]
311. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013; 105: 849-859 [PMID: 23704278 DOI: 10.1093/jnci/djt101]
312. Monzo M, Martínez-Rodenas F, Moreno I, Navarro A, Santasusagna S, Macias I, Muñoz C, Tejero R, Hernández R. Differential MIR-21 expression in plasma from mesenteric versus peripheral veins: an observational study of disease-free survival in surgically resected c olon cancer patients. Medicine (Baltimore) 2015; 94: e145 [PMID: 25569638 DOI: 10.1097/MD.0000000000000145]
313. Clancy C,Joyce MR,Kerin MJ. The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer Cancer Biomark 2015 15 103-113 PMID: 25547322 DOI: 10.3233/CBM-140456]
314. Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, Fujiwara H, Okamoto K, Otsuji E. Circulating long non-coding RNAs in plasma of p atients with gastric cancer. Anticancer Res 2013; 33: 3185-3193 [PMID: 23898077]
315. Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, Weng WW, Tan C, Sheng WQ, Zhou XY, Du X. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer 2015; Epub ahead of print [PMID: 25694351 DOI: 10.1002/ijc.29484]
316. Tong YS, Wang XW, Zhou XL, Liu ZH, Yang TX, Shi WH, Xie HW, Lv J, Wu QQ, Cao XF. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carci noma. Mol Cancer 2015; 14: 3 [PMID: 25608466]
317. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G, Chartrand P. An E2F/miR-20a autoregulat ory feedback loop. J Biol Chem 2007; 282: 2135-2143 [PMID: 17135249]
318. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3: 1 [PMID: 22230293 DOI: 10.1186/1758-907X-3-1]
319. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-726 [PMID: 17694064]
320. Bohen SP, Kralli A, Yamamoto KR. Hold 'em and fold 'em: chaperones and signal transduction. Science 1995; 268: 1303-1304 [PMID: 7761850]
321. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011; 71: 5214-5224 [PMID: 21690566 DOI: 10.1158/0008-5472. CAN-10-4645]
322. Terasawa K, Shimizu K, Tsujimoto G. Synthetic Pre-miRNABased shRNA as Potent RNAi Triggers. J Nucleic Acids 2011; 2011: 131579 [PMID: 21776374 DOI: 10.4061/2011/131579]
323. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009; 61: 746-759 [PMID: 19389436 DOI: 10.1016/j.addr.2009.04.004]
324. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-293 [PMID: 20055705 DOI: 10.1146/annurev.pharmtox.010909.105654]
325. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009; 19: 89-102 [PMID: 19441890 DOI: 10.1089/oli.2009.0180]
326. Citti L, Rainaldi G. Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr Gene Ther 2005; 5: 11-24 [PMID: 15638708]
327. Gredell JA, Berger AK, Walton SP. Impact of target mRNA structure on siRNA silencing efficiency: A large-scale study. Biotechnol Bioeng 2008; 100: 744-755 [PMID: 18306428 DOI: 10.1002/bit.21798]
328. Watrin M, Dausse E , Lebars I, Rayner B, Bugaut A, Toulmé JJ. Aptamers targeting RNA molecules. Methods Mol Biol 2009; 535: 79-105 [PMID: 19377979 DOI: 10.1007/978-1-59745-557-2-6]
329. Mascini M , Palchetti I, Tombelli S. Nucleic acid and peptide aptamers: fundamentals and bioanalytical aspects. Angew Chem Int Ed Engl 2012; 51: 1316-1332 [PMID: 22213382 DOI: 10.1002/anie.201006630]
330. Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther 2013; 21: 986-994 [PMID: 23481326 DOI: 10.1038/mt.2013.35]
331. Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S. The noncoding RNA MALAT1 is a critical regulato r of the metastasis phenotype of lung cancer cells. Cancer Res 2013; 73: 1180-1189 [PMID: 23243023 DOI: 10.1158/0008-5472.CAN-12-2850]
332. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013; 32: 1616-1625 [PMID: 22614017 DOI: 10.1038/onc.2012.193]
333. Zhao X, Pan F, Holt CM, Lewis AL, Lu JR. Controlled delivery of antisense oligonucleotides: a brief review of current strate gies. Expert Opin Drug Deliv 2009; 6: 673-686 [PMID: 19552611 DOI: 10.1517/17425240902992894]
334. Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets 2012; 16: 747-759 [PMID: 22690697 DOI: 10.1517/14728222.2012.696102]
335. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. Steroid and lipid conjugates o f siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004; 14: 4975-4977 [PMID: 15341962]
336. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010; 18: 1650-1656 [PMID: 20606648 DOI: 10.1038/mt.2010.136]
337. Tran TH, Mattheolabakis G, Aldawsari H, Amiji M. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin Immunol 2015; 160: 46-58 [PMID: 25842185 DOI: 10.1016/j.clim.2015.03.021]
338. Concepci on CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet 2012; 8: e1002797 [PMID: 22844244 DOI: 10.1371/journal. pgen.1002797]
339. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-M iller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 2013; 3: 1302-1315 [PMID: 24002999 DOI: 10.1158/2159-8290.CD-13-0159]
340. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011; 57: 833-840 [PMID: 21487102 DOI: 10.1373/clinchem.2010.157198]
341. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing the MicroRNA spectrum between serum and plasma. PLoS One 2012; 7: e41561 [PMID: 22859996 DOI: 10.1371/journal. pone.0041561]
342. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50: 298-301 [PMID: 20146939 DOI: 10.1016/j.ymeth.2010.01.032]
343. Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC. Plasma processing condition s substantially influence circulating microRNA biomarker levels. PLoS One 2013; 8: e64795 [PMID: 23762257 DOI: 10.1371/journal.pone.0064795]
344. Shan L, Ji Q, Cheng G, Xia J, Liu D, Wu C, Zh u B, Ding Y. Diagnostic value of circulating miR-21 for colorectal cancer: a metaanalysis. Cancer Biomark 2015; 15: 47-56 [PMID: 25524942 DOI: 10.3233/CBM-140437]
345. Jiang JX, Zhang N, Liu ZM, Wang YY. Detection of microRNA-21 expression as a potential screening biomarker for colorectal cancer: a meta-Analysis. Asian Pac J Cancer Prev 2014; 15: 7583-7588 [PMID: 25292032]
346. Xu F, Xu L, Wang M, An G, Feng G. The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-Analysis. Colorectal Dis 2015; 17: O100-O107 [PMID: 25683351 DOI: 10.1111/codi.12917]
347. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011; 57: 84-91 [PMID: 21036945 DOI: 10.1373/clinchem.2010.151845]
348. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-1179 [PMID: 20234369 DOI: 10.1038/sj.bjc.6605608]
349. Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K, Satoh K. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol 2015; 46: 539-547 [PMID: 25384963 DOI: 10.3892/ijo.2014.2743]
350. Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, Sun Q, Yan F, Yan C, Li H, Ren X. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-Analysis. Gene 2014; 533: 389-397 [PMID: 24076132 DOI: 10.1016/j.gene.2013.09.038]
351. Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L, Zhao C, Tao Y, Xu W. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep 2012; 5: 1514-1520 [PMID: 22406928 DOI: 10.3892/mmr.2012.828]
352. Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, Li X, Liao Q, Su B, Luo Z, Zhou Y, Zhou M, Zeng Z, Li X, Shen S, Shuai C, Li G, Fang J, Peng S. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One 2012; 7: e46367 [PMID: 23056289 DOI: 10.1371/journal.pone.0046367]
353. Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB. Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 2013; 58: 863-871 [PMID: 23390075 DOI: 10.1002/hep.26296]
354. Guo F, Tian J, Lin Y, Jin Y, Wang L, Cui M. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. J Int Med Res 2013; 41: 1456-1461 [PMID: 23963852 DOI: 10.1177/0300060 513487652]
355. Kawaguchi T,Komatsu S,Ichikawa D,Morimura R,Tsujiura M,Konishi H,Takeshita H,Nagata H,Arita T,Hirajima S,Shiozaki A,Ikoma H,Ok amoto K,Ochiai T,Taniguchi H,Otsuji E. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer Br J Cancer 2013 108 361-369 PMID: 23329235 DOI: 10.1038/bjc.2012.546
356. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, Shiozaki A, Ikoma H, Ok amoto K, Ochiai T, Taniguchi H, Otsuji E. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 2013; 108: 361-369 [PMID: 23329235 DOI: 10.1038/bjc.2012.546] 356 Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Morimura R, Nagata H, Kosuga T, Iitaka D, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011; 105: 104-111 [PMID: 21673684 DOI: 10.1038/bjc.2011.198]
357. Tokarz P, Blasiak J. The role of microRNA in metastati c colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol 2012; 59: 467-474 [PMID: 23173124]